Stifel Nicolaus Lowers Bolt Biotherapeutics (NASDAQ:BOLT) Price Target to $13.00

Bolt Biotherapeutics (NASDAQ:BOLTGet Rating) had its target price reduced by Stifel Nicolaus from $16.00 to $13.00 in a research report report published on Friday, The Fly reports.

Separately, Zacks Investment Research cut shares of Bolt Biotherapeutics from a buy rating to a hold rating in a research report on Friday, April 29th. Two equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of Buy and an average price target of $23.56.

Bolt Biotherapeutics stock traded down $0.04 during trading on Friday, hitting $1.52. The company had a trading volume of 166,478 shares, compared to its average volume of 292,546. Bolt Biotherapeutics has a 1-year low of $1.39 and a 1-year high of $20.49. The company has a quick ratio of 8.87, a current ratio of 8.87 and a debt-to-equity ratio of 0.09. The company’s 50 day simple moving average is $2.39 and its 200-day simple moving average is $4.65.

Bolt Biotherapeutics (NASDAQ:BOLTGet Rating) last issued its quarterly earnings results on Wednesday, March 30th. The company reported ($0.73) EPS for the quarter, beating the consensus estimate of ($0.81) by $0.08. Research analysts expect that Bolt Biotherapeutics will post -2.97 earnings per share for the current year.

Several institutional investors have recently added to or reduced their stakes in BOLT. Point72 Hong Kong Ltd purchased a new stake in shares of Bolt Biotherapeutics during the 3rd quarter worth $26,000. Royal Bank of Canada lifted its position in shares of Bolt Biotherapeutics by 206.9% during the 3rd quarter. Royal Bank of Canada now owns 2,437 shares of the company’s stock worth $31,000 after purchasing an additional 1,643 shares during the last quarter. Citigroup Inc. lifted its position in shares of Bolt Biotherapeutics by 154.6% during the 4th quarter. Citigroup Inc. now owns 7,236 shares of the company’s stock worth $35,000 after purchasing an additional 4,394 shares during the last quarter. Wells Fargo & Company MN lifted its position in Bolt Biotherapeutics by 16,830.9% in the fourth quarter. Wells Fargo & Company MN now owns 9,312 shares of the company’s stock valued at $45,000 after acquiring an additional 9,257 shares during the last quarter. Finally, ProShare Advisors LLC purchased a new stake in Bolt Biotherapeutics in the fourth quarter valued at $50,000. 89.78% of the stock is owned by institutional investors and hedge funds.

Bolt Biotherapeutics Company Profile (Get Rating)

Bolt Biotherapeutics, Inc, a clinical-stage biotechnology company, engages in the development of immuno-oncology agents to target tumor cells for elimination by the immune system. The company is developing BDC-1001, a human epidermal growth factor receptor 2 (HER2), which is in Phase I/II clinical trial for the treatment of patients with HER2-expressing solid tumors, including HER2-low tumors; BDC-2034, a carcinoembryonic antigen program for colorectal, non-small cell lung, pancreatic, and breast cancers; and BDC-3042, a Dectin-2 agonist antibody program developed to repolarize critical cells in the tumor microenvironment by targeting cell-surface receptors on macrophages.

Featured Stories

The Fly logo

Receive News & Ratings for Bolt Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bolt Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.